共 41 条
- [31] Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trialBRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (05) : 628 - 636Richardson, Paul G.Schlossman, Robert L.Roy, Anuja N.Panneerselvam, AshokAcharyya, SuddhasattaSopala, MonikaLonial, Sagar
- [32] PATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED, MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB (PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)HAEMATOLOGICA, 2015, 100 : 336 - 337Mesa, R.Vannucchi, A.Mead, A.Wang, L.Yang, Y.Harrison, C.
- [33] Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1288 - 1300Ganz, Patricia A.Bandos, HannaSpanic, TanjaFriedman, SueMueller, VolkmarKuemmel, SherkoDelaloge, SuzetteBrain, EtienneToi, MasakazuYamauchi, Hidekode Duenas, Eduardo-M.Armstrong, AnneIm, Seock-AhSong, Chuan-guiZheng, HongSarosiek, TomaszSharma, PriyankaGeng, CuizhiFu, PeifenRhiem, KerstinFrauchiger-Heuer, HeikeWimberger, Paulinede Roodenbeke, Daphne t'KintLiao, NingGoodwin, AnnabelChakiba-Brugere, CamilleFriedlander, MichaelLee, Keun SeokGiacchetti, SylvieTakano, ToshimiHenao-Carrasco, FernandoVirani, ShamsuddinValdes-Albini, FrancesDomchek, Susan M.Bane, CharlesMccarron, Edward C.Mita, MonicaRossi, GiovannaRastogi, PriyaFielding, AnitraGelber, Richard D.Scheepers, Elsemieke D.Cameron, DavidGarber, JudyGeyer, Charles E.Tutt, Andrew N. J.
- [34] Longitudinal patient-reported outcomes (PROs) and qualitative assessment of symptom burden within a phase 1b trial of a PARP inhibitor olaparib combined with an oral mTORC1/2 inhibitor (AZD2014) or an AKT inhibitor (AZD5363)QUALITY OF LIFE RESEARCH, 2018, 27 : S77 - S77Meyer, Larissa A.Sun, CharlotteShi, QiulingWestin, ShannonHaq, ShireenSavelieva, KaterinaColeman, RobertMills, GordonWilliams, Loretta
- [35] Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)EJC SUPPLEMENTS, 2009, 7 (02): : 265 - 265Dieras, V.Glaspy, J.Brufsky, A.Bondarenko, I.Lipatov, O.Perez, E. A.Chan, S.Zhou, X.Phan, S. C.Robert, N.
- [36] First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial.ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4171 - 4172Behrens, FrankOstergaard, MikkelStoilov, RumenWiland, PiotrHuizinga, Thomas W.Berenfus, Vadym Y.Tak, Paul-PeterVladeva, StoyankaRech, JuergenRubbert-Roth, AndreaKorkosz, MariuszRekalov, DmitriyZupanets, Igor A.Ejbjerg, Bo J.Geiseler, JensFresenius, JuliaKorolkiewicz, Roman P.Schottelius, Arndt J.Burkhardt, Harald
- [37] Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after?2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Richardson, Paul G.Lonial, SagarSchlossman, Robert L.Roy, Anuja NidumoluMajer, IstvanPanneerselvam, AshokSopala, MonikaMiguel, Jesus San
- [38] TERN-501, a highly selective thyroid hormone receptor β agonist, significantly improved MRI-PDFF, cT1, and liver volume in clinically relevant patient populations with presumed MASH: subgroup analyses from a 12-week phase 2a trialJOURNAL OF HEPATOLOGY, 2024, 80 : S607 - S607Harrison, Stephen A.Alkhouri, NaimNoureddin, MazenLawitz, EricKowdley, Kris V.Loomba, RohitLee, LoisJones, ChristopherQuirk, Erin
- [39] Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trialHEPATOLOGY, 2013, 58 : 737A - 738AForns, XavierLawitz, EricZeuzem, StefanGane, Edward J.Bronowicki, Jean-PierreAndreone, PietroHorban, AndrzejBrown, Ashley S.Peeters, MonikaLenz, OliverOuwerkerk-Mahadevan, SiviScott, Jane A.Kalmeijer, RonaldDe La Rosa, GuySinha, RekhaBeumont-Mauviel, Maria
- [40] Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialLANCET ONCOLOGY, 2018, 19 (08): : 1126 - 1134Friedlander, MichaelGebski, ValGibbs, EmmaDavies, LucyBloomfield, RalphHilpert, FelixWenzel, Lari B.Eek, DanielRodrigues, ManuelClamp, AndrewPenson, Richard T.Provencher, DianeKorach, JacobHuzarski, TomaszVidal, LauraSalutari, VandaScott, ClareNicoletto, Maria OrnellaTamura, KenjiEspinoza, DavidJoly, FlorencePujade-Lauraine, Eric